DIANTHUS THERAPEUTICS INC

Read Simon’s insider trade shows a 500% gain on Dianthus Therapeutics stock, revealing strategic short‑term profit tactics and potential short‑term rally signals for investors.

Insider buying at Dianthus Therapeutics shows executive confidence; Rule 10(b)(5) trades reveal a disciplined, plan‑based strategy boosting investor trust.

Insider Randhawa Simrat buys 27,000+ DIANTHUS shares at $8‑22 while selling 30,000+ at $90+—a bullish signal amid volatile 353% YTD gains, hinting future upside for investors.

Insight: Savitz Ryan’s April 2026 insider trades—buying at $17.88 and selling at $89.84—show a strategic confidence boost for Dianthus Therapeutics, blending long‑term stake with liquidity and market‑hedging, and hinting at potential upcoming corpor…

Insider trades by Dianthus Therapeutics’ CFO reveal a strategic balance of buying dips and selling highs amid a 53% rally, signaling confidence in its immunotherapy pipeline.

Insider buying surges as Dianthus raises $670 M, boosting shares 55% and signaling confidence in its antibody platform.